

Accepted Manuscript

Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter

V. Mangas-Sanjuan, C. Navarro-Fontestad, A. García-Arieta, I.F. Trocóniz, M. Bermejo



PII: S0928-0987(18)30089-7
DOI: <https://doi.org/10.1016/j.ejps.2018.02.014>
Reference: PHASCI 4411

To appear in: *European Journal of Pharmaceutical Sciences*

Received date: 7 November 2017

Revised date: 8 January 2018

Accepted date: 10 February 2018

Please cite this article as: V. Mangas-Sanjuan, C. Navarro-Fontestad, A. García-Arieta, I.F. Trocóniz, M. Bermejo, Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Phasci(2017), <https://doi.org/10.1016/j.ejps.2018.02.014>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

TITLE PAGE

Title: Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter

Authors names and affiliations: V Mangas-Sanjuan^{1, 2, 3, ¥}, C Navarro-Fontestad³, A García-Arieta^{4, a}, IF. Trocóniz², M Bermejo^{1, *}

¹ Engineering: Pharmacy and Pharmaceutical Technology Area. Miguel Hernandez University. Spain; ² Pharmacometrics & Systems Pharmacology, Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain; ³ Pharmacy and Pharmaceutical Technology Area. University of Valencia, Spain; ⁴ División de Farmacología y Evaluación Clínica, Departamento de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Productos Sanitarios. ^aThis manuscript represents the personal opinion of the authors and does not necessarily represent the views or policy of the Spanish Agency for Medicines and Health Care Products.

Present address: [¥]Pharmacy and Pharmaceutical Technology Area. University of Valencia, Spain

Corresponding author: *Corresponding author: Marival Bermejo, mbermejo@goumh.umh.es. Facultad de Farmacia, UMH, Carretera Alicante-Valencia, km 87, 03550 San Juan de Alicante, Alicante, Spain Phone +34 965919217. Fax +34 963544911

Download English Version:

<https://daneshyari.com/en/article/8511422>

Download Persian Version:

<https://daneshyari.com/article/8511422>

[Daneshyari.com](https://daneshyari.com)